Study Confirms Calcium L-Threonate Product Repairs Bone

FT. LAUDERDALE, Fla.A clinical study conducted by Jing Liang, MD, PhD, associate professor of molecular & medical pharmacology in the David Geffen School of Medicine at UCLA, found a patented calcium L-threonate supplement (as BioCalth®, from LTS Nutraceuticals, Inc.) was effective in repairing bone deterioration. The study looked at improvements to bone density and the formation of cartilage and collagen. Liang and his team showed BioCalth influence osteoblasts, which constantly reshape and mineralize bone tissue, but which can deplete with age.  The researchers reported the supplement helped increase osteoblast numbers and enhanced mineralization of osteoids (organic bone matrix).

Results also demonstrated BioCalth was absorbed by the osteoblasts five-times more than other calcium products compared in the study, increased osteoid collagen and activated alkaline phosphatase, which helps transform osteoid into mineralized or calcified extracellular matrix or new bone tissue.

"We continue to study the effects of BioCalth, as the product could potentially benefit over 40 million Americans that have an increased risk of bone fracture," Liang said. "We believe that BioCalth can be a candidate for therapeutic medication for Osteoporosis, Osteogenesis Imperfecta and other disease induced problems, bone mass loss or pain due to bone mass loss and even supplementary treatment after teeth-implants."

Jerry Rayman, CEO of LTS Nutraceuticals, noted, "BioCalth is only now being introduced to the U.S. market, and we believe with this research, the products' effectiveness, compared to other leading brands of calcium products, has been validated and we can expect to see a demand for BioCalth products throughout the retail channels."